Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) Patent Expiration, LOE Window & CMS Spending

Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) by Aurobindo Pharma: Off-Patent Genericized (AB Competition), 10 AB generics, $48.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurobindo Pharma
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$48.1M
2024 Medicare Part D Spend$23.3M
2024 Medicaid Spend$24.8M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 736.5% 2-yr change)